8-K: Labcorp Reports Strong 2025, Forecasts Robust 2026 Growth

Labcorp announced strong fourth quarter and full year 2025 financial results, driven by growth in Diagnostics and Central Laboratory businesses, and provided optimistic 2026 guidance.

Summary

• Full year 2025 revenue increased by 7.2% to $13.95 billion, up from $13.01 billion in 2024.
• Fourth quarter 2025 revenue grew 5.6% to $3.52 billion, compared to $3.33 billion in the prior year quarter.
• Full year 2025 adjusted EPS rose to $16.44, a double-digit increase from $14.57 in 2024.
• Fourth quarter 2025 adjusted EPS was $4.07, up from $3.45 in the same period of 2024.
• Full year 2025 free cash flow was $1.21 billion, an increase from $1.10 billion in 2024.
• Fourth quarter 2025 free cash flow decreased to $490.3 million from $665.1 million in Q4 2024, primarily due to working capital timing.
• Provided full-year 2026 guidance: revenue of $14.61 billion to $14.79 billion (midpoint growth of 5.4%), adjusted EPS of $17.55 to $18.25 (midpoint growth of 8.9%), and free cash flow of $1.24 billion to $1.36 billion (midpoint growth of 7.8%).
• Expanded partnerships by signing or closing 13 transactions with health systems and regional/local laboratories in 2025.
• Launched over 130 innovative new tests in 2025, including in oncology, women's health, neurology, and autoimmune.
• Announced a strategic investment to build a new 500,000 square foot Central Laboratory facility in Indiana, with construction expected to begin later in 2026.
• Launched the first FDA-cleared blood test for Alzheimer's disease assessment in primary care settings.
• Expanded access to molecular residual disease (MRD) testing for stage II-III breast cancer, stage II-IIIA non-small cell lung cancer, and stage III colon cancer.
• Repurchased $225 million of common stock in Q4 2025, bringing the full year total to $450 million.
• Declared a quarterly cash dividend of $0.72 per share, payable on March 12, 2026, to stockholders of record on February 27, 2026.
• Cash and cash equivalents balance was $532.3 million and total debt was $5.58 billion at December 31, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, demonstrating robust financial performance in 2025 and providing optimistic guidance for 2026, supported by strategic growth initiatives and innovation, despite a minor Q4 free cash flow dip.

Positives

• Strong full year 2025 revenue growth of 7.2% to $13.95 billion.
• Double-digit adjusted EPS growth for full year 2025, reaching $16.44.
• Significant margin expansion, with operating income as a percentage of revenue increasing by 160 basis points for the full year 2025.
• Robust full year 2025 free cash flow of $1.21 billion.
• Successful strategic expansion with 13 new partnerships/acquisitions in 2025, enhancing market presence.
• Leadership in specialty testing demonstrated by launching over 130 innovative new tests.
• Pioneering the first FDA-cleared blood test for Alzheimer's disease assessment in primary care, improving early diagnosis.
• Strategic investment in a new state-of-the-art 500,000 square foot Central Laboratory facility to support future growth.
• Positive 2026 guidance projecting continued growth in revenue (midpoint +5.4%), adjusted EPS (midpoint +8.9%), and free cash flow (midpoint +7.8%).
• Share repurchases totaling $450 million in 2025, returning value to shareholders.
• Biopharma Laboratory Services segment reported a healthy TTM Book-to-Bill ratio of 1.09 and a backlog of $8.72 billion, indicating strong future revenue visibility.

Negatives

• Fourth quarter 2025 free cash flow decreased to $490.3 million from $665.1 million in Q4 2024, primarily attributed to working capital timing.
• Early Development revenue within the Biopharma Laboratory Services segment was down 13.5% in Q4 2025.
• Cash and cash equivalents balance significantly decreased from $1,518.7 million at December 31, 2024, to $532.3 million at December 31, 2025.

Risks

• Failure to receive tax-free treatment for the spin-off of the former Clinical Development and Commercialization Services business for U.S. federal income purposes.
• Impact of spin-off related items on operations and financial results.
• Personnel costs and potential difficulties with employee relations and retention.
• Fluctuations in the company's stock trading price, competitive actions, and general marketplace uncertainties.
• Impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to their interpretation and application.
• Customer purchasing decisions, including changes in payer regulations or policies.
• Adverse actions of governmental and third-party payers.
• Changes in testing guidelines or recommendations.
• Impact of global geopolitical events.
• Effect of public opinion on the company's reputation.
• Adverse results in material litigation matters.
• Failure to maintain or develop customer relationships.
• Ability to develop or acquire new products and adapt to technological changes.
• Failure of the company's information technology, systems, or data security.
• Impact of potential losses under repurchase agreements.
• Adverse weather conditions affecting operations.
• Variations in the number of revenue days in a financial period.
• Inflationary pressures on costs and operations.
• Increased competition in the laboratory services market.
• Effect of exchange rate fluctuations on financial results.

Future Outlook

Labcorp projects continued strong performance in 2026, with enterprise revenue guidance of $14.61 billion to $14.79 billion (5.4% midpoint growth), adjusted EPS of $17.55 to $18.25 (8.9% midpoint growth), and free cash flow of $1.24 billion to $1.36 billion (7.8% midpoint growth). The company remains focused on growth, strategic partnerships, and innovation, including the new Central Laboratory facility expected to begin construction later in 2026.

Management Comments

• "In 2025, Labcorp grew revenue over 7% and delivered double-digit adjusted EPS growth, margin expansion and strong free cash flow. Performance was driven by continued strength in our Diagnostics and Central Laboratory businesses."
• "We made significant progress across our strategic priorities, and we begin 2026 with strong momentum, and expect continued strong performance in 2026 as we remain focused on growth."

Industry Context

StockSavvy.ai notes that Labcorp's continued expansion through strategic acquisitions and partnerships with health systems aligns with a broader trend in the healthcare diagnostics industry towards consolidation and integrated service offerings. The launch of innovative tests, particularly the FDA-cleared Alzheimer's blood test and expanded MRD testing, positions Labcorp at the forefront of precision medicine and early disease detection, reflecting a key industry focus on advanced diagnostics. The investment in a new state-of-the-art central laboratory facility indicates a commitment to scaling infrastructure to meet growing demand, a common challenge and opportunity for major players in the lab services sector.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies' results or global benchmarks.
• Labcorp's support for over 85% of new drugs and therapeutic products approved by the FDA in 2025 highlights a significant market presence in drug development support, a key metric for contract research organizations (CROs) and central labs.
• The Biopharma Laboratory Services segment's TTM Book-to-Bill ratio of 1.09 indicates healthy demand and future revenue visibility, generally considered a positive sign in the contract research organization (CRO) and central lab industry, suggesting new orders are outpacing revenue recognition.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased EPS, share repurchases ($450 million in 2025), and a declared quarterly dividend of $0.72 per share.
• Customers (Doctors, Hospitals, Patients): Enhanced access to a broad menu of routine and specialty tests, including innovative new tests like the FDA-cleared Alzheimer's blood test and expanded MRD testing, improving patient care and diagnostic capabilities.
• Employees: Continued growth and strategic investments (e.g., new Central Lab facility) suggest stability and potential for future opportunities.
• Suppliers: Increased demand and strategic investments may lead to increased business for suppliers involved in facility construction and technology implementation.

Next Steps

• Construction of the new 500,000 square foot Central Laboratory facility in Indiana is expected to begin later in 2026.
• A quarterly cash dividend of $0.72 per share is payable on March 12, 2026, to stockholders of record on February 27, 2026.
• A conference call discussing Labcorp's quarterly results was scheduled for February 17, 2026, at 9:00 a.m. ET.

Key Dates

Recommendation

The company delivered robust full-year 2025 financial results with significant revenue and adjusted EPS growth, demonstrating strong operational execution in its core Diagnostics and Central Laboratory segments. The optimistic 2026 guidance, projecting continued growth in revenue, adjusted EPS, and free cash flow, coupled with strategic investments in new facilities and innovative test launches (e.g., FDA-cleared Alzheimer's test), indicates a strong growth trajectory. Share repurchases further enhance shareholder value. Despite a minor Q4 free cash flow dip, the overall performance and outlook suggest a compelling investment opportunity.

Keywords

Labcorp, LH, Diagnostics, Biopharma, Laboratory Services, Financial Results, EPS, Revenue, Free Cash Flow, 2025 Results, 2026 Guidance, Specialty Testing, Healthcare, Acquisitions, Share Repurchase, Alzheimer's Test, Cancer Testing, Central Laboratory